why choose us

First received: February 07, 2023

Clinical Trial: Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Phase 2 Single Arm Trial With a Safety Lead-in of Tucatinib in Combination With Doxil for the Treatment of HER2+ Metastatic Breast Cancer

Brief Summary: This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer.The main goals of this study are to:Learn how well the combination of tucatinib and Doxil worksLearn more about the side effects of the combination of tucatinib and Doxil

Read more